Breaking News Bar
updated: 7/28/2014 7:41 AM

Virus drugmaker fights pediatricians' new advice

hello
Success - Article sent! close
 

A drugmaker is clashing with pediatricians over new recommendations to limit use of a costly medicine for preventing serious lung problems in preemies and other high-risk children.

The dispute involves new American Academy of Pediatrics guidelines that say medical evidence shows the drug has limited benefits. The influential group says the drug is best suited for only very young preemies.

Order Reprint Print Article
 
Interested in reusing this article?
Custom reprints are a powerful and strategic way to share your article with customers, employees and prospects.
The YGS Group provides digital and printed reprint services for Daily Herald. Complete the form to the right and a reprint consultant will contact you to discuss how you can reuse this article.
Need more information about reprints? Visit our Reprints Section for more details.

Contact information ( * required )

Success - request sent close

The drug is sold by MedImmune under the brand name Synagis. MedImmune is fighting back with full-page newspaper ads that say the updated policy threatens the most vulnerable babies.

The drug is used to prevent problems linked with a common germ called RSV or respiratory syncytial (sin-SISH'-uhl) virus. Most kids get it but only mild cases with cold-like symptoms.

The new policy was published online Monday in Pediatrics.

Share this page
Comments ()
Guidelines: Keep it civil and on topic; no profanity, vulgarity, slurs or personal attacks. People who harass others or joke about tragedies will be blocked. If a comment violates these standards or our terms of service, click the X in the upper right corner of the comment box. To find our more, read our FAQ.